Category Archives: SPBIO

The ‘No Pivot’, Black Swan

September 22, 2023 By in $SPSIBI, Biotech, Federal Reserve, LABD, Nissam Taleb, Positions, SPBIO, Van Metre 1 Comment

Then, There’s Biotech

Back in January, this post was contrary to the accepted (and still accepted) theory, there’ll be a Fed ‘pivot’ when the economy turns south.

‘Like ‘bread and circuses’, the ‘pivot’ discussion is a distraction … keeping the proletariat placated.’

We went south a long time ago and not only is there no pivot, rates are most likely going higher still (not advice, not a recommendation).

A Process Of Iteration

Those accessing this site for any length of time, have seen my trading actions going through a process of iteration in real-time.

Those actions have effectively searched (and profited) from moves, but more importantly, are looking for the market that stands to decline the farthest and fastest.

At this juncture, that market could be biotech and specifically, the SPBIO, index (not advice, not a recommendation).

Biotech SPBIO, Monthly

Depending on if, when, and where the neckline is broken, we have an approximate location for a measured move.

Head & Shoulders patterns, while being high probability, can be subject to failure.

One of the most famous of these in recent memory, was the S&P Head and Shoulders of late 2002.

It was an easily recognizable pattern that failed … only later to find out, the market had been manipulated higher by an entity (buying futures contracts) that had ‘unlimited capital’.

Positioning

As this post detailed, the main position going short the index (via LABD) has already been opened (not advice, not a recommendation).

There have been other additions, but they are nowhere near the size of the original entry.

Hard Stop has been moved up from LABD 17.59 to LABD 18.22 (not advice, not a recommendation).

Highly Leveraged, LABD

There’s no guarantee, 3X Leveraged Inverse fund LABD, will be maintained throughout a potential collapse. Events can change, even while this post is being created.

That being said, what’s happening here is akin to ‘settling in’ on a trade, monitoring price action, trend lines, and support/resistance, to mentally prepare for what could be a sustained move.

So far, that approach is working.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Good News, Bad News … Biotech

September 19, 2023 By in $SPSIBI, 1907, Biotech, LABD, Livermore, Positions, SPBIO, The List, Wyckoff 4 Comments

When Price Action Heads South

One of the first things a professional (mentor) will teach aspiring traders, is:

‘Big money potential is on the downside’.

A famous example of this, was during the Panic of 1907,

Jesse Livermore raised capital by hawking his car for $5,000 (according to Wyckoff), then shorted the market.

Near the bottom on (or about) October 24th, 1907, he covered; netting over $1 million in profits.

That Was Then … Is That Now?

Well, conditions change, but human behavior does not.

Back in the day, it was newspapers, telephone, telegraph and ‘rumors’; today, we have Cramer 🙂

You’ll have to judge for yourself if the posts on this site are providing worthwhile insight.

Let’s move on to Biotech, SPBIO.

Since I am short this sector via LABD (not advice, not a recommendation), we’re going to look at that vehicle.

Biotech Leveraged Inverse LABD, Daily

After the entry on 9/14, at 16.99, price action has not looked back.

Note, the entry had a very tight stop as covered here.

The ‘risk’ is determined as the distance from entry to stop; in the case above, 16.99 – 16.66 = 0.33-pts.

For example, a ‘risk’ of $1,000 let’s say, equates to a position size just over 3,000 shares LABD (not advice, not a recommendation).

Trending

The chart shows LABD, is currently trending higher at an aggressive rate.

There’s no guarantee this will continue to hold.

However, at the same time, there’s been no ‘news generating’ breakout, either.

So, at this point, it’s all under the radar.

Bad News Comes Out

When price action heads south, bad news comes out.

On a daily basis now, with articles like this and this.

Positioning

The initial position has already been discussed.

Other minor ones have been opened but the more important part, is Stop placement.

The initial Stop has been moved from LABD 16.66 to yesterday’s low of LABD 17.59 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The ‘Event Horizon’

September 16, 2023 By in $SPSIBI, CBDC, Daniela Cambone, Edward Dutton, Excess Deaths, LABD, Positions, SPBIO, Wyckoff, ZeroHedge 3 Comments

Set In Motion

Serious students of the markets discover quickly enough, price action has nothing to do with forecasts or fundamentals.

Once that mental hurdle is overcome, the market landscape takes on a whole new meaning.

Moving Parts, A-Plenty

At present, there’re a lot of moving parts but a few things are known: the on-going population collapse, the soon-to-be market and currency collapse (or severe de-basement), the possible ‘balkanization‘ of the U.S., just for starters.

Those wheels have already been set in motion.

Within that construct, are the market navigations (trading actions) presented on this site.

Biotech Has Spoken

At least for now, the bears are in control (not advice, not a recommendation).

The minor ‘spring’ set-up, materialized during Thursday’s session, just as this update said was likely.

It’s what happened next, that’s important.

On Friday, the set-up failed; showing the higher probability is for more downside.

Biotech SPBIO, Daily

Price action is posting lower.

The potential trading channel has been re-drawn with the grey lines; indicating the possibility for more aggressive downside action (not advice, not a recommendation).

Positioning

As can be inferred with these updates, I’ve already positioned short this sector via leveraged inverse fund LABD (not advice, not a recommendation).

The stop is Thursday’s high (SPBIO, 6,135.81) which corresponds to LABD 16.66 (interesting, that).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The AI ‘Hot Potato’

September 14, 2023 By in $SPSIBI, Artificial Intelligence, LABD, SOXS, SOXX, SPBIO, The Maverick of Wall Street, Wyckoff 2 Comments

My Forecast Is Hotter Than Yours!

Those on the bear side of the AI insanity, know in their gut, this sector’s going to implode in spectacular fashion (not advice, not a recommendation).

The question is, as The Maverick puts it, ‘when’?

What’s also not known, is how the public is going to react when the punch bowl is taken away and we have the day of reckoning.

With that in mind, the immediate downside in the SOXX, has failed to materialize … just yet.

Therefore, all short positions via SOXS, have been closed; profit was about +10%

Behind The Scenes … Biotech

Biotech, SPBIO, has been an on-again, off-again opportunity.

It’s not known how the next ‘planned outbreak’ is going to affect the sector, but it looks like at this point, the current response is to edge lower.

Biotech SPBIO, Weekly

The big picture shows lower highs as we head toward well-established support zones.

From a trading and shorting perspective, the leveraged inverse fund for this sector is LABD (not advice, not a recommendation).

Biotech SPBIO, Daily

Moving closer in, the daily action has penetrated prior lows, technically putting the index in Wyckoff spring position.

Price action will likely attempt a move higher, happening now during this session.

If that move fails, then we have our answer; the bulls would be exhausted (for now).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Back To The ‘Elephant’

July 28, 2023 By in $SPSIBI, LABD, Positions, SOXS, SOXX, SPBIO, The Speck

The ‘AI’ Dog Keeps Biting

Upward price action in the SOXX, held overnight and then some.

A discretionary exit was made in the pre-market session at SOXS 8.42 (not advice, not a recommendation).

Switching gears, we’re leaving the SOXX and AI alone for now.

As mentioned in a prior post, the life insurance sector appears to be correlated with biotech. It’s a fact the life insurance companies are talking a hit from ‘excess’ payouts.

We all know or should know just what’s causing the ‘excess’, so we’ll leave it there.

That leads to the biotech sector (SPBIO) and what appears to be a downside reversal.

Biotech SPBIO ($SPSIBI), Weekly

When looking at the chart for the past three years, one thing is certain; this is not a bull market.

The blue arrow shows the location of a short position opened (via LABD @ 14.70) in today’s pre-market session (not advice, not a recommendation).

A Hard Stop for the position is LABD 13.31.

Since that’s a fair distance from the entry, a discretionary exit may be made by the trader at any time based on the behavior of price action going forward.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

AI, ‘Train-Wreck’, Leaves Station

July 20, 2023 By in $SPSIBI, Biotech, Edward Dowd, LABD, NVDA, Positions, Semiconductors, SOXS, SOXX, SPBIO, TSM

Did You See The ‘Elephant’ ?

It’s hidden in plain sight.

Taiwan Semi (TSM) releases lackluster results, revenue slowdown and new building construction delays.

TSM says the delays stem from the inability to find qualified workers.

Edward Dowd provides insight on the overall reduction of employees, in this interview (Time stamp 5:10).

Bull Trap Shut, Train Leaving Station

If there ever was a ‘gotcha’ moment, this is it.

Even while the mainstream continues to tout the hype, here, here and here, the market has reversed (not advice, not a recommendation).

The daily chart of SOXX, has the MACD bearish divergence confirmed. Price action is now (as of 3:05 p.m., EST) well below the breakout (blue line) resistance area.

Semiconductor SOXX, Daily

This site does not give advice, but it can be inferred by reading the reports what actions are being executed (not advice, not a recommendation).

With that said, short positions in the SOXX, via leveraged inverse SOXS, were entered early during yesterday’s session at SOXS 8.54 and SOXS 8.69.

As a side note, within minutes after today’s market open, the gain in the SOXS, fully erased the -7.9% loss via LABD, noted in yesterday’s update.

The Biotech ‘Bid’

For whatever reason, probably to be revealed months or years from now, biotech, the instigator of the ‘elephant’ is not selling off into a market collapse as expected.

Instead, the effects are being played out in low-margin industries like airlines and semiconductors.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Last of The Bubble(s)

July 19, 2023 By in $SPSIBI, Biotech, LABD, Positions, Semiconductors, SOXS, SOXX, SPBIO, TSM 1 Comment

‘Idol’ Worship

If Artificial Intelligence, really is the last of the bubble(s), isn’t it appropriate we culminate in a market top of the ages, with the desire (and delusion) that we can be like God.

Let’s ask ‘AI’ how to get rid of spike protein … see what it says.

We’re around mid-day; the SOXX, is raging a bull/bear battle inside the range of yesterday’s session.

Tuesday’s session was not able to post a new high or low. With that said, the Fibonacci count from the last update remains intact.

Semiconductor SOXX, Daily

The chart shows upside pressure (volume) is dissipating.

As of this post, the MACD (not shown) is flat, waiting to tick lower; not yet confirming the bearish divergence.

A penetration of the prior session low, SOXX 524.11, would give a classical analysis sell signal (not advice, not a recommendation).

Tomorow’s TSM Earnings

Anything can happen.

SOXX, could spike higher to the previously identified 550- 560, area.

Or, we could have an immediate ‘sell the news’ event.

Either way, it’s up to the speculator/trader to decide for himself whether to take action, or not.

Biotech Short

Separately, the biotech short via LABD, has been exited with a – 7.9%, loss. So, there’s that.

On to the next trade (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

BridgeBio … Buy or Sell ?

July 17, 2023 By in $SPSIBI, BBIO, Biotech, LABD, Positions, SPBIO

Or … Just Another ‘Pump & Dump‘

Seems like anything related to the heart is all the rage these days.

‘Protein‘, Anyone?

So, it is with BridgeBiopharma (BBIO), currently the number three in market cap on the S&P biotech Index, SPBIO.

The daily chart shows the extent of the day’s move.

BridgeBiopharma (BBIO), Daily

Note that price action did NOT gap above resistance but pushed up to that area during the session; backing off (slightly) before the close.

Correspondingly, the leveraged inverse fund LABD had a rough day in the early session.

However, that down move was already starting to erode before the close.

Biotech Leveraged Inverse LABD, Daily

The blue arrow shows price action closed well off the lows (blue line).

Tomorrow, there are a number of data releases scheduled, link here before the open, then during the early session.

Expectations

While still maintaining a short position via LABD (not advice, not a recommendation), the expectation is BBIO, has the garden variety pump-and-dump.

We’ve all seen this movie before … right?

That is, completion of a ‘trial’ is a long way from ‘approval’ and then manufacturing start-up.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Fibonacci, Force and Biotech

July 12, 2023 By in $SPSIBI, LABD, Positions, SPBIO, The List, The Speck, Wyckoff, ZeroHedge

Waiting For The ‘Event Horizon’

We’re going to start first, with this link, presenting the on-going fundamentals of the sector.

For those of us literally pulling their hair out, wondering if the dam is ever going to break, we have this link.

‘We’ve just poisoned 5-Billion people …’

Note: The dam break is the ‘event horizon’ where everyone collectively wakes-up. Once that happens, the ‘conspiracy’ has been proven as undeniable fact.

Biotech SPBIO, may or may not have an absolute direct connection with the aforementioned links but it’s the ‘baby with the bathwater’ response that’s expected.

Adding to that, big players in this sector have no P/E

The top-ten weightings keep changing, but the last time it was checked, none in the top-ten, had a P/E.

Since we’re working the short side, it’s the leveraged inverse fund LABD that’s of interest.

Biotech Leveraged Inverse LABD, Daily

Note the near perfect Fibonacci time correlation.

As of today’s close, price action on the LABD has got itself into a Wyckoff ‘spring position’ having decisively penetrated support (blue line), shown below.

That spring set-up has been accomplished on weak down-thrust when compared to the prior move lower.

We have a high probability of upside reversal, down for SPBIO (not advice, not a recommendation).

Positioning

Stated in the prior update, we’re short this sector (long LABD) and now have Hard Stop @ LABD 13.27 (not advice, not a recommendation).

Update: 7/13/23, 2:51 p.m. EST

LABD price action pushed to 13.26, just 0.01, below the above listed stop and is now moving higher.

Trade has been maintained (not advice, not a recommendation)

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

SOXX … The ‘AI’ Wedge Higher

July 11, 2023 By in $SPSIBI, Biotech, DWCINL, LABD, Life Insurance, Positions, Semiconductors, SOXS, SOXX, SPBIO 1 Comment

Last Gasp Before August 23rd?

The SOXX chart pattern (below), is telling us we’re likely in a case of …’buy the rumor, sell the news’.

Yesterday’s action may have negated any immediate reversal downward.

Now, it looks like we’re going into a terminating wedge targeting SOXX higher to approximately 550 – 560 (not advice, not a recommendation).

Of course, anything can happen.

Semiconductor SOXX, Daily

Note, the potential for a bearish MACD divergence if SOXX moves to new highs.

If we thought there was hysteria now, just think what’s it’s going to be like if SOXX breaks to the upside.

Party, like it’s 1999

Then, Biotech SPBIO

Meanwhile back at the ranch, with about a half-hour to go before the regular session, biotech leveraged inverse LABD, is hovering at yesterday’s lows.

Biotech SPBIO, Leveraged Inverse LABD, Daily

Support (blue line) has been penetrated.

Price action has stopped dead … thus far.

This sector has been the downside leader (LABD, higher) in the past so, we’ll see if that’s happening now.

The ‘Life Insurance’ Correlation

There appears to be correlation with potential downside reversal in biotech and possible downside reversal in the life-insurance sector.

We’ll discuss that in another update.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279